Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

Phase 2

Withdrawn

• Conditions: Multiple Myeloma
• Interventions: Drug: panobinostat (capsules); Drug: carfilzomib (infusion); Drug: dexamethasone (tablets)

• Registration Number: NCT02756663
• Lead Sponsor: Novartis Pharmaceuticals

Brief Summary

The purpose of this study is to investigate the anti-myeloma effect of panobinostat given at two different doses (10 mg and 20 mg oral) in combination with carfilzomib (20/56 mg/m2 i.v.) and low dose dexamethasone (20 mg oral) vs carfilzomib plus low-dose dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma. Safety and efficacy will be evaluated. Treatment will be administered in 4-week cycles until patients discontinue due to disease progression or unacceptable toxicity or for other reasons.

Patients who discontinue the study treatment for reasons other than documented disease progression will be followed for disease assessments every 8 weeks until progression. All patients will be followed for survival until 3 years have passed from their entry into the study, or they have discontinued the follow up earlier.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-04-12
• Study First Submitted QC: 2016-04-26
• Study First Posted: 2016-04-29
• Status Verified: 2016-11
• Last Update Submitted: 2016-11-07
• Last Update Posted: 2016-11-08
• Study Start: 2016-12
• Primary Completion: 2021-02
• Study Completion: 2021-02

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Previous diagnosis of MM based on IMWG definitions (Rajkumar, 2014)
• Prior treatment with 1 to 3 prior lines of therapy
• Relapsed or relapsed and refractory MM
• Measureable disease at screening based on central laboratory assessment
• ECOG Performance status ≤ 2
• Acceptable lab values prior to starting study treatment

Read More

Exclusion Criteria

• Primary refractory myeloma
• Prior treatment with DAC inhibitors including panobinostat
• Prior treatment with carfilzomib
• Allogeneic stem cell transplant recipient with graft versus host disease (either active or requiring immunosuppression)
• Any concomitant anti-cancer therapy besides the study treatment (bisphosphonates are permitted only if commenced prior to the start of screening period)
• Intolerance to dexamethasone or contraindication to carfilzomib or dexamethasone
• Unresolved diarrhea ≥ CTCAE grade 2 or a medical condition associated with chronic diarrhea (such as irritable bowel syndrome, inflammatory bowel disease)

Other protocol-defined inclusion/exclusion criteria may apply.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm A: PAN (10mg) + CFZ + Dex	dexamethasone (tablets)	Panobinostat (PAN) 10mg orally, combined with carfilzomib (CFZ) 20/56 mg/m2 i.v. and dexamethasone (Dex) 20mg orally, in 4 week cycle
Arm B: PAN (20mg) + CFZ + Dex	dexamethasone (tablets)	Panobinostat (PAN) 20mg orally, combined with carfilzomib (CFZ) 20/56 mg/m2 i.v. and dexamethasone (Dex) 20mg orally, in 4 week cycle
Arm B: PAN (20mg) + CFZ + Dex	carfilzomib (infusion)	Panobinostat (PAN) 20mg orally, combined with carfilzomib (CFZ) 20/56 mg/m2 i.v. and dexamethasone (Dex) 20mg orally, in 4 week cycle
Arm C: CFZ + Dex	carfilzomib (infusion)	Carfilzomib (CFZ) 20/56 mg/m2 i.v. and dexamethasone (Dex) 20mg orally, in 4 week cycle
Arm A: PAN (10mg) + CFZ + Dex	panobinostat (capsules)	Panobinostat (PAN) 10mg orally, combined with carfilzomib (CFZ) 20/56 mg/m2 i.v. and dexamethasone (Dex) 20mg orally, in 4 week cycle
Arm A: PAN (10mg) + CFZ + Dex	carfilzomib (infusion)	Panobinostat (PAN) 10mg orally, combined with carfilzomib (CFZ) 20/56 mg/m2 i.v. and dexamethasone (Dex) 20mg orally, in 4 week cycle
Arm B: PAN (20mg) + CFZ + Dex	panobinostat (capsules)	Panobinostat (PAN) 20mg orally, combined with carfilzomib (CFZ) 20/56 mg/m2 i.v. and dexamethasone (Dex) 20mg orally, in 4 week cycle
Arm C: CFZ + Dex	dexamethasone (tablets)	Carfilzomib (CFZ) 20/56 mg/m2 i.v. and dexamethasone (Dex) 20mg orally, in 4 week cycle

Primary Outcome Measures

Name	Time	Method
Overall response rate (ORR) using investigator's response assessment	All patients treated for 6 cycles (cycle=28 days)	The primary endpoint if Overall Response Rate (ORR) using investigator response assessment according to IMWG criteria. The analysis of ORR will be performed after all randomized patients have completed 6 months of study treatment or discontinued treatment earlier.

Secondary Outcome Measures

Name	Time	Method
Progression-free survival (PFS) using investigator's response assessment based on IMWG criteria	All patients treated for 6 cycles (cycle=28 days)	PFS is defined as the time from date of randomization to date of first documented disease progression or death (regardless of cause of death).
Overall survival (OS)	All patients treated for 6 cycles (cycle=28 days)	OS is defined as the time from date of randomization to the date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of last contact.
Minimum observed plasma concentration (Cmin) for carfilzomib	All patients treated for 6 cycles (cycle=28 days)	The minimum (trough) observed plasma concentration after single and multiple dose administration (ng/mL) of PAN and CFZ.
Concentration of panobinostat in blood plasma in 48 hrs after the dose.	All patients treated for 6 cycles (cycle = 28 days)	The area under the concentration-time curve (AUC) from time zero to 48 hours (ng\*h/mL) after the dose of PAN
Very Good Partial Response (VGPR) or better as best response using investigator response assessment based on International Myeloma Working Group (IMWG) criteria	All patients treated for 6 cycles (cycle=28 days)	Investigators' response assessment assessed on IMWG criteria will be used. The VGPR or better rate is defined as the proportion of patients with a confirmed VGPR or better response as their best overall response.
Time to response (TTR) using investigator's response assessment based on IMWG criteria	All patients treated for 6 cycles (cycle=28 days)	TTR is the time between date of randomization to the date of first onset of partial response (PR) or better response.
Duration of Response (DOR) using investigator's response assessment based on IMWG criteria	All patients treated for 6 cycles (cycle = 28 days)	DOR is defined as the duration from the first documented onset of PR or better response the date of first documented disease progression or death due to multiple myeloma. DOR will use only the patients with PR or better as their best response.
Time to progression (TTP) using investigator's response assessment based on IMWG criteria	All patients treated for 6 cycles (cycle = 28 days)	TTP is defined as the time from the date of randomization to the ate of the first documented disease progression or death due to multiple myeloma.
Time to reach Cmax for panobinostat (PAN) and carfilzomib (CFZ)	All patients treated for 6 cycles (cycle=28 days);	The maximum (peak) observed plasma concentration after single and multiple dose administration (ng/mL) of PAN and CFZ.
Total carfilzomib exposure over time in blood plasma .	All patients treated for 6 cycles (cycle=28 days)	The AUC from time zero to infinity (ng\*h/mL) for CFZ.
Health related quality of life (HRQoL) change over time measured by EORTC questionnaire QLQ-C30 and QLQ-MY20 for disease symptoms	All patients treated for 6 cycles (cycle=28 days)	HRQoL questionnaires are patient reported outcomes, which provide functional assessment of cancer therapy.